BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
INTRODUCTION
Authors did a very basic introduction with general concepts. Introduction should be more elaborated according to the current evidence. Is it necessary to define "off-label use" using Wikipedia as reference? Authors analyzed off-label drug prescribing in terms of indication and the age of patient. However, they did analyze neither other relevant aspects that they pointed out in the limitations, nor other significant aspects such as previous treatment for the same indication, concomitant drug use. The objective of this study seems to be more related to the education and training to general practice interns in France than to analyze off-label drug prescribing.
METHODS

According to authors' information, this study is a part of a research program (OPREM). Did the Ethics and Research
Committee approve this sub-study (research protocol)? Authors should provide the number assigned. Authors included some information in "Participants" section of the abstract . However, in the Methods section (page 9, lines 16-18) they wrote "Patient and Public Involvement … None". However, Authors in the "Inclusion criteria" said, "Eight patients refused to participated to the study". All this information should be clarified. If patients were requested to participate in the study, did they read and sign the informed consent and information full to them? How authors estimated the sample size? As for sample size collected, is it a representative sample for general practice representing prescribing in France? Besides, it seems a short period of collecting data (2-month and 5 days per office) to overtake some of the limitations of the study such as bias owed to trainers (n=11) and their potential interindividual variability. Page 11, , authors should explain the following sentence, since clinical guidelines are elaborated according to SPC: "Off-label prescribing is indeed not always wrong or harmful, especially when complying with clinical guidelines". Page 12, (line 35-27) , SCP has to be changed by SPC.
DISCUSSION
REFERENCES
Authors used many references that are useful for their country. It reveals this study would have more relevance and be more applicable at a national level than at an international level. This is a well-written and interesting paper. The discussion of French laws on off-label prescribing put the results of the study in context and the conclusions of the study are appropriate. I have a few minor comments for the authors consideration:
VERSION 1 -AUTHOR RESPONSE
Abstract: "to consensually define off-label prescription" may be clearer if the authors change to "to clearly define off-label use by consensus", or similar.
We have changed the wording accordingly.
Page 12, line 35-I think it should be SPC, not SCP We have corrected this typing error.
Page 12-lines, 44 and 48-I suggest saying "the branded versions of" rather than "the original".
We have changed the wording as suggested.
Pages 12 and 13-For the discussion on paediatric off-label use, it might be worth mentioning that some drugs may later obtain an MA for use in children although such use was originally off-label. It's also worth noting that real-word evidence on use in such off-label populations is sometimes used to providing supporting evidence for MA applications in new populations.
We have integrated these arguments in due place within the Comparison with existing literature subsection.
INTRODUCTION
Authors did a very basic introduction with general concepts. Introduction should be more elaborated according to the current evidence.
Is it necessary to define "off-label use" using Wikipedia as reference?
We have complemented the introduction, especially concerning the presentation of the marketing authorization in the US, as compared to Europe: "The FDA-approved labelling for a drug provides the Prescribing Information or Package Insert (PI) to the practitioners and the Patient Package Insert (PPI) to the patients. The PI contains two main components: the highlights of prescribing information (HPI) and the full prescribing information (FPI).3". We have also added this sentence: "However, there is substantial disagreement in the information available to prescribers and patients in different countries.8"
As addressed at the end of the Discussion section, there is no official, international definition for offlabel prescribing and various definitions are used. We have changed the reference from Wikipedia with the reference from the European Medicines Agency, as follows: "Any intentional use of an authorised product not covered by the terms of its marketing is considered an off-label prescription. This may for example be the use for a different indication, use of a different dosage, dosing frequency or duration of use, use of a different method of administration, or use by a different patient group."
Authors analyzed off-label drug prescribing in terms of indication and the age of patient. However, they did analyze neither other relevant aspects that they pointed out in the limitations, nor other significant aspects such as previous treatment for the same indication, concomitant drug use. The objective of this study seems to be more related to the education and training to general practice interns in France than to analyze off-label drug prescribing.
Although we agree with the limitations of the study, that we have indeed pointed out in the corresponding section, we disagree with the last comment. This is an epidemiological, cross-sectional study. Its implications at international level are fully discussed in the Implications for practice and research section. They partly refer to the education of the interns, but also to the improvement of the drug prescription software, the development of the post-marketing surveillance and the issue of a consensual definition for off-label prescribing. Actually, despite its limitations, this study is original as there has been very few previous studies estimating the frequency of off-label prescribing in general practice worldwide.
METHODS
According to authors' information, this study is a part of a research program (OPREM). Did the Ethics and Research
Committee approve this sub-study (research protocol)? Authors should provide the number assigned.
The Ethics Committee approved the OPREM research program and the present study was conducted to address one of its secondary objectives. We have complemented the Ethics approval section and indicated the number assigned by the Committee, as follows: "The Ethics Committee of the Hospices Civils de Lyon approved the OPREM research program, including the present study (N°15-02)." Authors included some information in "Participants" section of the abstract . However, in the Methods section (page 9, lines 16-18) they wrote "Patient and Public Involvement … None". However, Authors in the "Inclusion criteria" said, "Eight patients refused to participated to the study". All this information should be clarified.
We have specified in the Patient and Public involvement subsection the following that "The patients were asked their oral consent to collecting their data for the purpose of the study." Regarding the few patient refusals to participate, we have clarified the wording of the concerned sentence in the Methods section by specifying that "the 2149 patients who came for a medical consultation or were visited at home were requested to participate to the study". In the abstract, we have specified "All the voluntary patients…".
If patients were requested to participate in the study, did they read and sign the informed consent and information full to them?
We have answered above to this question.
How authors estimated the sample size? As for sample size collected, is it a representative sample for general practice representing prescribing in France?
We calculated a sample size of 2119 consultations, based on estimates of 2.9 drugs prescribed per consultation on average21 and of 20% of drugs prescribed off-label11 with a confidence interval of ±1%. This point has been added in the Inclusion criteria subsection.
We already mentioned the possible influence of the recruitment of GP trainers in the subsection Strenghs and limitations of the Discussion. In addition, we could compare the mean age (49.8 yrs vs 51.7, p=0.35) and gender (69.6% of males vs 60.7%, p=0.51) of participating GPs and French GPs in 2016. We have reported in the manuscript that we found no difference.
Besides, it seems a short period of collecting data (2-month and 5 days per office) to overtake some of the limitations of the study such as bias owed to trainers (n=11) and their potential inter-individual variability.
We recognize that the study duration was relatively short. It was sufficient, however, to exceed the minimum sample size expected. In addition, the multilevel model adjusted for the variability between the 23 (not 11) trainers.
DISCUSSION
Page 11, (lines 25-27), authors should explain the following sentence, since clinical guidelines are elaborated according to SPC: "Off-label prescribing is indeed not always wrong or harmful, especially when complying with clinical guidelines".
We agree that usually clinical practice guidelines are based on SPC. But there are some exceptions, among which we have reported two examples among the ten most prescribed off-label drugs identified in our study:
-Acetylsalicylic acid has no indication for peripheral artery disease while it is recommended by the French National Authority for Health (HAS) in that indication,29,30 -Omeprazole is also not indicated for the prevention of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) induced lesions, while it is one of the proton pump inhibitors (at full dose) recommended by the HAS in this indication.32
To make the sentence clearer, we have specified "especially when complying with clinical practice guidelines, since they are usually elaborated according to SPC." Page 12, , SCP has to be changed by SPC. This change has been done.
REFERENCES
Authors used many references that are useful for their country. It reveals this study would have more relevance and be more applicable at a national level than at an international level.
We have sharply decreased the number of references specific to France, by either removing or changing for an international reference. Among them, we have just kept the references which are needed to make the methods explicit and to interpret the results in the appropriate context.
We think that our findings are thus introduced and discussed with more relevance to the international readership. Page 36 (lines 38-39). Authors have included a new sentence based on the reference number 8. Since this reference refers to a study carried out more than fifteen years ago (in 2003) , it had better no express this sentence in present tense or if they prefer change the way of introducing this information by the name of the author.
VERSION 2 -REVIEW
REVIEWER
We have changed the tense in this sentence, as follows: "However, there has been substantial disagreement in the information available to prescribers and patients in different countries.8"
